THE DIAGNOSTIC USE OF AMOBARBITAL SODIUM ("AMYTAL SODIUM") IN BRAIN DISEASE
Abstract
The use of amobarbital sodium (amytal sodium R) as a diagnostic test for brain disease is described. In 57 of 88 patients with proven brain disease, who on clinical examination showed no disturbances in behavior, the intravenous administration of the drug produced patterns of disorientation for time, place, and person and denial of illness. These changes were not obtained in any of 50 control patients. The applicability of the procedure to the study of alterations in brain function caused by structural, iatrogenic, metabolic, and toxic agents is discussed.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
